[1]张春.NHS-MAG3在放射性药物标记中的应用[J].国际放射医学核医学杂志,2001,25(3):97-100.
　ZHANG Chun.Application of NHS-MAG3 in the radioparmaceuticals labeling[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(3):97-100.
点击复制

NHS-MAG3在放射性药物标记中的应用(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
25
期数:
2001年第3期
页码:
97-100
栏目:
综述
出版日期:
1900-01-01

文章信息/Info

Title:
Application of NHS-MAG3 in the radioparmaceuticals labeling
作者:
张春
610041 成都, 华西医科大学附一院核医学科
Author(s):
ZHANG Chun
Department of Nuclear Medicine, the Affiliated Hospital, the West China University of Medical Sciences, Sichuan Chengdu 610041, China
关键词:
巯基乙酰三甘氨酰-N-羟基丁二酰亚胺酯; 双功能螯合剂; 放射性核素标记
Keywords:
N-hydroxysuccinimidyl S-acetylmercaptoacetyltriglycline; bifunctional chelator; radionuclide labeling
分类号:
R817
摘要:
随着分子核医学的迅速发展,一种有效标记蛋白质、小分子肽和DN A寡核苷酸的双功能螯合剂NHS-MAG3(巯基乙酰三甘氨酰-N-羟基丁二酰亚胺酯)应运而生。研究表明,利用NHS-MAG3进行99Tcm标记,得到的标记物的标记率和比放射性高,体内外稳定性好,与血清蛋白的非特异结合低,为核医学提供了多种具有广阔临床应用前景的诊断和治疗的放射性药物。
Abstract:
With the rapid development of molecular nuclear medicine, N-hydroxysuccinimidyl S-acetylmercap-toacetyltriglycline (NHS-MAG3) as one effective bifunctional chelator has been used to radiolabel proteins, small peptides and DNA oligonucleotides with 99Tcm. The lable by the MAG3-labeling method show high labeling efficiencies and high specific activities and hold desirable stability in vitro and in vivo. The binding of the lable with plasma protein is low. So many potentially useful radioparmaceuticals for diagnosis and therapy may be produced via the NHS-MAG3 method.

参考文献/References:

[1] Winnard P Jr,Chang F,Rusckowski M,et al.Prepa-ration and use of NHS-MAG3 for technetium-99m label-ing of DN A[J].Nucl Med Biol,1997,24(5):425-432.
[2] Gano L,Patricio L,Marques E,et al.Human polyclonal immunoglobulin labelled with technetium-99m via NHS-MAG3:a comparison of radiochemical behav-ior and biological efficacy with other labelling methods[J].Nucl Med Biol,1998,25(4):395-403.
[3] Hnatowich DJ,Qu T,Chang F,et al.Labeling peptidewith technetium-99m using a bifunctional chelator of a N-hydroxysuccinimide ester of mercaptoacetyltrigiycine[J].J Nucl Med,1998,39(1):56-64.
[4] Lei K,Rusckowski M,Chang F,et al.Technetium-99mantibody labeled with MAG3 and SHNH:an in vitro andanimal in vivo comparison[J].Nucl Med Biol,1996,23(7):917-922.
[5] Rusckowski M,Qu T,Pullman J,et al.Inflammationand infection imaging with a 99mTc-neutrophil elastaseinhibitor in monkeys[J].J Nucl Med,2000,41(2):363-374.
[6] Mardirossian G,Lei K,Rusckowski F,et al.In vivohybridization of technetium-99m-labeled peptide nucleicacid (PNA)[J].J Nucl Med,1997,38(6):907-913.
[7] Pallela V R,Thakur M L,Chakder S,et al.99Tcm-la-beled vasoactive intestinal peptide receptor agonist:functional studies[J].J Nucl Med,1999,40(2):352-360.
[8] Hnatowich DJ,Mardirossian G,Fogarasi M,et al.Comparative properties of a Technetium-99m-labeledsingle stranded natural DN A and a phosphorothioatederivative in vitro and in mice[J].J Pharmacol Exp Ther,1996,276(1):326~334.
[9] Callahan RJ,Barrow SA,Abrams M J,et al.Biodistri-bution and dosimetry of Technetium-99m-hydrazinonicotinamide IgG:Comparison with Indium-111 DTPA-IgG[J].J Nucl Med,1996,37(6):843-846.

相似文献/References:

[1]兰晓莉.两种99Tcm标记双功能螯合剂:NHS-MAG3和HYNIC[J].国际放射医学核医学杂志,2005,29(1):15.
　LAN Xiao-li.Two bifunctional chelating agents used in 99Tcm labeling: NHS-MAG3 and HYNIC[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(3):15.

备注/Memo

备注/Memo:
收稿日期:2000/7/3。
基金项目:国家自然科学基金资助项目(39870200)
作者简介:张春(1973-),女,山西长治人,华西医科大学附属第一医院核医学科博士研究生,主要从事反义治疗研究。
更新日期/Last Update: 1900-01-01